Cellular Biomedicine Reports Positive China CAR-T Cancer Data

Cellular Biomedicine Group, a China-California cell therapy company, reported positive data from a small trial of its Chimeric Antigen Receptor (CAR-T) immunotherapy for CD30-positive Hodgkin's lymphoma. In a heavily pretreated group of patients, five of seven participants responded to the treatment. Earlier this year, CBMG formed a partnership with the Chinese PLA 301 General Hospital of Beijing to develop the technology, which was discovered by the 301 Hospital. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //